Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2537-2545

  Watanabe, Takako ^a   Sakamoto, Naoya ^a   Nakagawa, Mina ^a   Kakinuma, Sei ^a   Itsui, Yasuhiro ^b   Nishimura Sakurai, Yuki ^a   Ueyama, Mayumi ^a   Funaoka, Yusuke ^a   Kitazume, Akiko ^a   Nitta, Sayuri ^a   Kiyohashi, Kei ^a   Murakawa, Miyako ^a   Azuma, Seishin ^a   Tsuchiya, Kiichiro ^a   Oooka, Shinya ^a   Watanabe, Mamoru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Soka Municipal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON; INTERFERON REGULATORY FACTOR 9; INTERFERON STIMULATED GENE FACTOR 3; MYXOVIRUS RESISTANCE PROTEIN A; PROTEIN KINASE R; PROTEIN P56; STAT1 PROTEIN; STAT2 PROTEIN; TOOSENDANIN; TRITERPENOID; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; VIRUS REPLICATION; WESTERN BLOTTING;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; RNA, VIRAL; VIRUS REPLICATION;

EID: 79956303543     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01780-10     Document Type: Article

References (48)

1. Agrawal, S., and E. R. Kandimalla. 2007. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem. Soc. Trans. 35:1461-1467.
2. Bailey, M., N. A. Williams, A. D. Wilson, and C. R. Stokes. 1992. PROBIT: weighted probit regression analysis for estimation of biological activity. J. Immunol. Methods 153:261-262.
3. Baldwin, A. S., Jr. 2001. Series introduction: the transcription factor NF-kappaB and human disease. J. Clin. Invest. 107:3-6.
4. Esimone, C. O., et al. 2008. Potential anti-respiratory syncytial virus lead compounds from Aglaia species. Pharmazie 63:768-773.
5. Esimone, C. O., et al. Dammarenolic acid, a secodammarane triterpenoid from Aglaia sp. shows potent anti-retroviral activity in vitro. Phytomedicine 17:540-547.
6. Fried, M. W., et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
7. Funaoka, Y., et al. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. J. Virol., in press.
8. Ge, D., et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
9. Goodbourn, S., L. Didcock, and R. E. Randall. 2000. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81:2341-2364.
10. Hadziyannis, S. J., et al. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346-355.
11. Hiasa, Y., et al. 2008. Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta. Hepatology 48:59-69.
12. Horsmans, Y., et al. 2005. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42:724-731. (Pubitemid 41233667)
13. Itsui, Y., et al. 2009. Antiviral effects of the interferon-induced protein guanylate binding protein 1 and its interaction with the hepatitis C virus NS5B protein. Hepatology 50:1727-1737.
14. Itsui, Y., et al. 2006. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. J. Viral Hepat. 13:690-700. (Pubitemid 44401198)
15. Jiang, D., et al. 2008. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J. Virol. 82:1665-1678. (Pubitemid 351206918)
16. Kalvakolanu, D. V. 2003. Alternate interferon signaling pathways. Pharmacol. Ther. 100:1-29.
17. Kanazawa, N., et al. 2004. Regulation of hepatitis C virus replication by interferon regulatory factor 1. J. Virol. 78:9713-9720. (Pubitemid 39187089)
18. Karakama, Y., et al. 2010. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. Antimicrob. Agents Chemother. 54:3179-3186.
19. Karin, M., and A. Lin. 2002. NF-kappaB at the crossroads of life and death. Nat. Immunol. 3:221-227.
20. Kuntzen, T., et al. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-1778.
21. Lindenbach, B. D., et al. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. (Pubitemid 41033648)
22. Mishima, K., et al. 2010. Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants. Virology 405:361-369.
23. Nakagawa, M., et al. 2005. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 129:1031-1041. (Pubitemid 41242693)
24. Randall, R. E., and S. Goodbourn. 2008. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89:1-47.
25. Sadler, A. J., and B. R. Williams. 2008. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8:559-568.
26. Sakamoto, N., and M. Watanabe. 2009. New therapeutic approaches to hepatitis C virus. J. Gastroenterol. 44:643-649.
27. Sakamoto, N., et al. 2007. Bone morphogenetic protein-7 and interferon-alpha synergistically suppress hepatitis C virus replicon. Biochem. Biophys. Res. Commun. 357:467-473.
28. Samuel, C. 2001. Antiviral actions of interferons. Clin. Microbiol. Rev. 14:778-809.
29. Sangiovanni, A., et al. 2006. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 43:1303-1310. (Pubitemid 43980109)
30. Sekine-Osajima, Y., et al. 2008. Development of plaque assays for hepatitis C virus-JFH1 strain and isolation of mutants with enhanced cytopathogenicity and replication capacity. Virology 371:71-85.
31. Shi, Y. L., and M. F. Li. 2007. Biological effects of toosendanin, a triterpenoid extracted from Chinese traditional medicine. Prog. Neurobiol. 82:1-10.
32. Shi, Y. L., and Z. F. Wang. 2004. Cure of experimental botulism and antibotulismic effect of toosendanin. Acta Pharmacol. Sin. 25:839-848.
33. Soothill, J. S., R. Ward, and A. J. Girling. 1992. The IC50: an exactly defined measure of antibiotic sensitivity. J. Antimicrob. Chemother. 29:137-139.
34. Suda, G., et al. IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. Virology 407:80-90.
35. Suppiah, V., et al. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41:1100-1104.
36. Tada, K., M. Takido, and S. Kitanaka. 1999. Limonoids from fruit of Melia toosendan and their cytotoxic activity. Phytochemistry 51:787-791. (Pubitemid 29289200)
37. Tanabe, Y., et al. 2004. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J. Infect. Dis. 189:1129-1139.
38. Tanaka, Y., N. Nishida, M. Sugiyama, K. Tokunaga, and M. Mizokami. Lambda-interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Hepatol. Res. 40:449-460.
39. Taniguchi, T., K. Ogasawara, A. Takaoka, and N. Tanaka. 2001. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19:623-655.
40. Taniguchi, T., and A. Takaoka. 2002. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr. Opin. Immunol. 14:111-116.
41. Thompson, A. J., and J. G. McHutchison. 2009. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J. Viral Hepat. 16:377-387.
42. Wakita, T., et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
43. Yokota, T., et al. 2003. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 4:602-608. (Pubitemid 36939952)
44. Zeuzem, S., et al. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343:1666-1672.
45. Zhang, B., Z. F. Wang, M. Z. Tang, and Y. L. Shi. 2005. Growth inhibition and apoptosis-induced effect on human cancer cells of toosendanin, a triterpenoid derivative from Chinese traditional medicine. Invest. New Drugs 23:547-553.
46. Zhang, J. H., T. D. Chung, and K. R. Oldenburg. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73.
47. Zhang, Y., et al. 2008. Roles of reactive oxygen species and MAP kinases in the primary rat hepatocytes death induced by toosendanin. Toxicology 249:62-68.
48. Zhong, J., et al. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 102:9294-9299.